Latest Growth Strategy News

Fortescue Metals Group delivered record iron ore shipments in FY25 alongside a rare cost decline, while recalibrating its green energy ambitions and maintaining a strong financial position.

St Barbara Limited is progressing towards the renewal of its Simberi Mining Lease, a critical step to extend operations and boost gold production through 2038. Final approval is anticipated in August 2025 after regulatory review delays.

Deep Yellow Limited reports significant progress at its flagship Tumas uranium project in Namibia and successful pilot testing at Mulga Rock in Australia, supported by a robust cash position of A$217.4 million.

Northern Star Resources delivered record underlying free cash flow in FY25 and is advancing its KCGM Mill Expansion into the final build year, positioning the company for growth in FY26 and beyond.

Hiremii Limited reported a 4.4% revenue increase in Q4 FY25 alongside positive operating cash flow, while accelerating commercialisation of its proprietary AI recruitment platform and expanding through a key acquisition.

Canadian Phosphate Limited advances its Canadian operations with new bulk sampling permits and a promising exploration target, while steady sales and customer upgrades signal growth ahead.

Mantle Minerals has agreed to sell its Mt Roe gold project subsidiary for $13.5 million, marking a pivotal step in its growth strategy. The company also secured a government drilling grant for its Mt Berghaus project and raised $250,000 to support ongoing operations.

Hillgrove Resources outlined its operational progress and growth strategy at the Noosa Mining Investor Conference, highlighting strong cash flow and resource expansion at its Kanmantoo Copper Gold Mine.

Aerometrex has completed a strategic review that delivers $2 million in cost savings and initiates data monetisation, positioning the company for accelerated growth in FY26.

Elsight Limited has raised A$60 million through a strongly supported placement, marking a milestone with consecutive record revenues and cash flow breakeven. The company is poised to capitalize on surging defence budgets and expanding drone markets with a robust pipeline of opportunities.

Firebrick Pharma has published positive Phase 3 clinical trial results for its Nasodine nasal spray, showing efficacy against the common cold, while reporting encouraging sales growth in Singapore and the US. However, a recent capital raise fell well short of targets, casting uncertainty over its expansion plans.

Streamplay Studio Limited has posted a positive operating cash flow for the first time since its acquisition-led growth strategy began, buoyed by strong game launches and a new multi-year licensing agreement with Amazon.